BR112018010879A2 - inibidores da proteína quinase, método de preparação e uso médico dos mesmos - Google Patents
inibidores da proteína quinase, método de preparação e uso médico dos mesmosInfo
- Publication number
- BR112018010879A2 BR112018010879A2 BR112018010879-0A BR112018010879A BR112018010879A2 BR 112018010879 A2 BR112018010879 A2 BR 112018010879A2 BR 112018010879 A BR112018010879 A BR 112018010879A BR 112018010879 A2 BR112018010879 A2 BR 112018010879A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- present
- preparation
- medical use
- mesomer
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
- 239000003909 protein kinase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 9
- 239000000203 mixture Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 208000003174 Brain Neoplasms Diseases 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000002547 new drug Substances 0.000 abstract 1
- 238000009522 phase III clinical trial Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510856641.1 | 2015-11-30 | ||
| CN201510856641.1A CN106810536A (zh) | 2015-11-30 | 2015-11-30 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
| PCT/CN2016/107455 WO2017092635A1 (zh) | 2015-11-30 | 2016-11-28 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018010879A2 true BR112018010879A2 (pt) | 2018-11-21 |
Family
ID=58796287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018010879-0A BR112018010879A2 (pt) | 2015-11-30 | 2016-11-28 | inibidores da proteína quinase, método de preparação e uso médico dos mesmos |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11091476B2 (https=) |
| EP (1) | EP3385262B1 (https=) |
| JP (2) | JP6921101B2 (https=) |
| KR (1) | KR20180083421A (https=) |
| CN (3) | CN106810536A (https=) |
| AU (1) | AU2016365366B2 (https=) |
| BR (1) | BR112018010879A2 (https=) |
| CA (1) | CA3002884A1 (https=) |
| CO (1) | CO2018005854A2 (https=) |
| DK (1) | DK3385262T3 (https=) |
| ES (1) | ES2928169T3 (https=) |
| HU (1) | HUE060152T2 (https=) |
| IL (1) | IL259711B (https=) |
| MA (1) | MA42341B2 (https=) |
| MX (1) | MX387207B (https=) |
| PH (1) | PH12018550049A1 (https=) |
| PT (1) | PT3385262T (https=) |
| RU (1) | RU2749437C2 (https=) |
| UA (1) | UA124001C2 (https=) |
| WO (1) | WO2017092635A1 (https=) |
| ZA (1) | ZA201803531B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106810536A (zh) * | 2015-11-30 | 2017-06-09 | 甘李药业股份有限公司 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
| AU2018354972B2 (en) | 2017-10-27 | 2021-07-08 | Fresenius Kabi Oncology Ltd. | An improved process for the preparation of ribociclib and its salts |
| WO2019161224A1 (en) | 2018-02-15 | 2019-08-22 | GiraFpharma LLC | Heterocyclic compounds as kinase inhibitors |
| WO2019170055A1 (zh) * | 2018-03-05 | 2019-09-12 | 上海海和药物研究开发有限公司 | 具有cdk4/6激酶抑制活性的化合物、其药用组合物和用途 |
| AU2020215684B2 (en) * | 2019-01-29 | 2025-08-21 | Beta Pharma, Inc. | 2h-indazole derivatives as therapeutic agents for brain cancers and brain metastases |
| AR119184A1 (es) * | 2019-06-21 | 2021-12-01 | Gan & Lee Pharmaceuticals | Sales de un compuesto, formas cristalinas de las sales y método de preparación y uso de las mismas |
| CN114364668B (zh) * | 2019-06-21 | 2024-07-16 | 甘李药业股份有限公司 | Cdk4/6抑制剂、及其盐和中间体的制备方法 |
| WO2022042738A1 (zh) * | 2020-08-31 | 2022-03-03 | 甘李药业股份有限公司 | 一种含cdk4/6抑制剂的药物组合物 |
| US11685744B2 (en) * | 2020-09-21 | 2023-06-27 | Prelude Therapeutics Incorporated | CDK inhibitors and their use as pharmaceuticals |
| IL316942A (en) * | 2020-12-18 | 2025-01-01 | Prelude Therapeutics Inc | CDK inhibitors and their use as drugs |
| CN112390793B (zh) * | 2021-01-19 | 2021-04-27 | 中国药科大学 | Cdk6/dyrk2双靶点抑制剂及其制备方法和应用 |
| CN117222636A (zh) * | 2021-04-12 | 2023-12-12 | 甘李药业股份有限公司 | 作为cdk4/6抑制剂的氘代化合物 |
| WO2022242563A1 (zh) * | 2021-05-17 | 2022-11-24 | 甘李药业股份有限公司 | 一种cdk4/6抑制剂的医药用途 |
| WO2023040914A1 (zh) * | 2021-09-14 | 2023-03-23 | 甘李药业股份有限公司 | 一种cdk4/6抑制剂的医药用途 |
| CN118339157A (zh) * | 2021-12-24 | 2024-07-12 | 江苏恒瑞医药股份有限公司 | 氢化吲哚类化合物、其制备方法及其在医药上的应用 |
| CN115093397B (zh) * | 2022-06-07 | 2023-09-05 | 自贡市第三人民医院 | 一种用于治疗肿瘤的化合物、合成方法及应用 |
| CN117658987A (zh) * | 2022-09-08 | 2024-03-08 | 上海深势唯思科技有限责任公司 | 作为plk1抑制剂的化合物及其制备方法和用途 |
| WO2024066986A1 (zh) * | 2022-09-30 | 2024-04-04 | 楚浦创制（武汉）医药科技有限公司 | 2-氨基嘧啶类化合物及其应用、药用组合物 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9619284D0 (en) | 1996-09-16 | 1996-10-30 | Celltech Therapeutics Ltd | Chemical compounds |
| JP2003521543A (ja) | 2000-02-07 | 2003-07-15 | アボット ゲーエムベーハー ウント カンパニー カーゲー | ２−ベンゾチアゾリル尿素誘導体およびそのプロテインキナーゼ阻害剤としての使用 |
| ES2251677T3 (es) * | 2002-01-22 | 2006-05-01 | Warner-Lambert Company Llc | 2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-onas. |
| JP2007520558A (ja) | 2004-02-04 | 2007-07-26 | スミスクライン・ビーチャム・コーポレイション | キナーゼ阻害剤として有用なピリミジノン化合物 |
| KR20080110998A (ko) | 2006-01-30 | 2008-12-22 | 엑셀리시스, 인코포레이티드 | Ｊａｋ２ 조절자로서 ４아릴２아미노피리미딘 또는 4아릴２아미노알킬피리미딘 및 이들을 포함하는 약제학적 조성물 |
| WO2008124085A2 (en) | 2007-04-03 | 2008-10-16 | Exelixis, Inc. | Methods of using combinations of mek and jak-2 inhibitors |
| WO2009017838A2 (en) * | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
| US8309566B2 (en) | 2008-02-15 | 2012-11-13 | Rigel Pharmaceuticals, Inc. | Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases |
| EP2283009B1 (en) | 2008-05-16 | 2012-08-29 | F. Hoffmann-La Roche AG | Inhibitors of jnk |
| JO2885B1 (en) * | 2008-12-22 | 2015-03-15 | ايلي ليلي اند كومباني | Protein kinase inhibitors |
| UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
| US20130310340A1 (en) * | 2012-05-16 | 2013-11-21 | Rigel Pharmaceuticals, Inc. | Method of treating muscular degradation |
| EP2909194A1 (en) * | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| CN106608879A (zh) | 2015-10-27 | 2017-05-03 | 甘李药业股份有限公司 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
| CN106810536A (zh) | 2015-11-30 | 2017-06-09 | 甘李药业股份有限公司 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
| KR102765806B1 (ko) | 2017-09-05 | 2025-02-10 | 블랙손 테라퓨틱스, 인크. | 바소프레신 수용체 길항제 및 그와 관련된 제품 및 방법 |
| CN117222636A (zh) | 2021-04-12 | 2023-12-12 | 甘李药业股份有限公司 | 作为cdk4/6抑制剂的氘代化合物 |
-
2015
- 2015-11-30 CN CN201510856641.1A patent/CN106810536A/zh active Pending
-
2016
- 2016-11-28 IL IL259711A patent/IL259711B/en unknown
- 2016-11-28 CN CN202111217526.1A patent/CN113956238B/zh active Active
- 2016-11-28 EP EP16869945.2A patent/EP3385262B1/en active Active
- 2016-11-28 HU HUE16869945A patent/HUE060152T2/hu unknown
- 2016-11-28 UA UAA201806447A patent/UA124001C2/uk unknown
- 2016-11-28 CN CN201680064053.7A patent/CN108290864B/zh active Active
- 2016-11-28 PT PT168699452T patent/PT3385262T/pt unknown
- 2016-11-28 JP JP2018546737A patent/JP6921101B2/ja not_active Expired - Fee Related
- 2016-11-28 MA MA42341A patent/MA42341B2/fr unknown
- 2016-11-28 MX MX2018006370A patent/MX387207B/es unknown
- 2016-11-28 WO PCT/CN2016/107455 patent/WO2017092635A1/zh not_active Ceased
- 2016-11-28 CA CA3002884A patent/CA3002884A1/en active Pending
- 2016-11-28 RU RU2018122864A patent/RU2749437C2/ru active
- 2016-11-28 DK DK16869945.2T patent/DK3385262T3/da active
- 2016-11-28 US US15/778,812 patent/US11091476B2/en not_active Expired - Fee Related
- 2016-11-28 KR KR1020187017438A patent/KR20180083421A/ko active Pending
- 2016-11-28 ES ES16869945T patent/ES2928169T3/es active Active
- 2016-11-28 BR BR112018010879-0A patent/BR112018010879A2/pt not_active Application Discontinuation
- 2016-11-28 AU AU2016365366A patent/AU2016365366B2/en not_active Ceased
-
2018
- 2018-04-23 PH PH12018550049A patent/PH12018550049A1/en unknown
- 2018-05-28 ZA ZA2018/03531A patent/ZA201803531B/en unknown
- 2018-06-06 CO CONC2018/0005854A patent/CO2018005854A2/es unknown
-
2021
- 2021-06-08 JP JP2021095588A patent/JP2021138737A/ja active Pending
- 2021-07-30 US US17/444,109 patent/US11787801B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018010879A2 (pt) | inibidores da proteína quinase, método de preparação e uso médico dos mesmos | |
| BR112022004495A8 (pt) | Compostos oxinitreto de piridina, composição farmacêutica compreendendo os mesmos e usos dos mesmos | |
| BR112014017985A8 (pt) | Combinação de um inibidor de rtk com um antiestrogênio e uso da mesma para o tratamento de cancer | |
| MX2013008673A (es) | Derivados del tipo del azaindazol o diazaindazol como medicamento. | |
| EA201800064A1 (ru) | 1,1,1-трифтор-3-гидроксипропан-2-ил карбаматные производные и 1,1,1-трифтор-4-гидроксибутан-2-ил карбаматные производные в качестве ингибиторов magl | |
| EA201070167A1 (ru) | Замещенные производные индазола, активные как ингибиторы киназы | |
| EA201691151A1 (ru) | Соединения для лечения пациентов с ros1-мутантными раковыми клетками | |
| BR112019022512A2 (pt) | Compostos de heteroarila bicíclica fundida 6-6 e seu uso como inibidores de lats | |
| BR112015012366A8 (pt) | antagonistas de cxcr7, uso dos mesmos, composição farmacêutica, bem como métodos para detectar níveis elevados de cxcr7 em uma amostra e para imagear um tumor, órgão, ou tecido | |
| NI201000145A (es) | DERIVADOS DE IMIDAZO - [1, 2-b] - PIRIDAZINA PARA EL TRATAMIENTO DE ENFERMEDAD MEDIADA POR CINASA DE TIROSINA C-MET. | |
| BR112013021537A2 (pt) | derivados de tiazolilpenil-benzenosulfonamido como inibidores da quinase | |
| DK2324008T3 (da) | Diarylpyrazol som protein kinase inhibitorer | |
| BR112013014914B8 (pt) | composto, composição farmacêutica e uso de um composto | |
| BRPI1014572B8 (pt) | Imidazopirazinas para uso como inibidores de cinase | |
| PH12015500313A1 (en) | Orally administered medical composition | |
| BRPI0713923B8 (pt) | compostos de ciclopentanos de pirimidila hidroxilados e metoxilados, composição farmacêutica compreendendo os referidos compostos, método de preparação de um composto, e uso dos mesmos | |
| ECSP13012852A (es) | Derivados de 6-ciclobutil-1,5-dihidro-pirazolo [3,4-d]pirimidin-4-ona y su uso como inhibidores de pde9a. | |
| AU2013269809B2 (en) | Biomarkers for determining effective response of treatments of Hepatocellular carcinoma (HCC) patients | |
| CL2020001097A1 (es) | Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6. | |
| EA201200318A1 (ru) | Гетероциклические оксимы | |
| BR112015028212A2 (pt) | derivado de fenol e método de preparação e utilização dos mesmos na medicina | |
| RU2014144254A (ru) | Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение | |
| MX387785B (es) | Compuestos heteroarilo y su uso como farmacos terapeuticos. | |
| BR112013017362A2 (pt) | composto de fórmula (i), processo para preparar um composto de fórmula (i), composição farmacêutica e compostos, métodos e usos inovadores | |
| CA2831932A1 (en) | Combinations of akt and mek inhibitor compounds, and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |